Immunic Inc. Stock News

Immunic (IMUX) stock is falling hard on Thursday after the company released poor results from a recent Phase 2 clinical trial. The post Why is Immunic (IMUX) Stock Plunging 40% Today?

Immunic Inc. (NASDAQ:IMUX ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Daniel Vitt – Chief Executive officer, President & Director Glenn Whaley – Vice President

– Webcast to be Held at 8:00 am ET on May 10, 2022 – NEW YORK, May 3, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selec

Immunic Inc. (IMUX) CEO Daniel Vitt on Q4 2021 Results - Earnings Call Transcript

Immunic press release (IMUX): FY GAAP EPS of -$3.93 misses by $0.04.Cash and Cash Equivalents as of December 31, 2021 were $86.9M

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chroni

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chro

Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.

The consensus price target hints at a 357.4% upside potential for Immunic (IMUX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate

Wall Street analysts forecast that Immunic, Inc. (NASDAQ:IMUX) will announce earnings per share of ($0.73) for the current quarter, Zacks reports. Zero analysts have made estimates for Immunics earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($0.78). Immunic reported earnings of ($0.46) per share in the []

Immunic (NASDAQ:IMUX)s stock had its buy rating reissued by HC Wainwright in a report released on Monday, Analyst Ratings Network reports. They currently have a $25.00 price target on the stock. HC Wainwrights price objective would suggest a potential upside of 150.75% from the companys current price. Several other research firms have also commented on []

Brokerages expect that Immunic, Inc. (NASDAQ:IMUX) will report ($0.75) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Immunics earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.86). Immunic reported earnings per share of ($0.46) during the same quarter last year, which indicates a []

DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potenti…